RESUMEN
The aim of this study was determined the expression of pro inflammatory cytokines in prostate epithelial cells. Furthermore, we analysed the relation between these cytokines and sera PSA levels according the three groups: 0-4, 4-20 and >20 ng/mL. The study was carried out in five normal prostate (NP), 27 benign prostate hyperplastic (BPH) and 18 prostate cancer (PC). Immunohistochemical and Western blot analysis was performed. Serum levels of PSA were assayed by Immulite autoanalyser. The western Blotting analysis revealed an immunoexpression of IL-1alpha, IL-6 and TNFalpha in BPH and PC. IL-1alpha, was absent in NP. Immunohistochemical analysis showed significant high optical density to IL-1alpha and IL-6 in cancer epithelial cells (19.45 +/- 3.25 and 26.2 +/- 3.19) compared to normal cells (1.73 +/- 1.51 and 4.83 +/- 2.65). While, TNFalpha optical densities were not significant in NP (12.03 +/- 2.9), BPH (9.87 +/- 3.85) and PC (13.34 +/- 2.34). The different profiles of cytokines according sera PSA levels showed a high immunoexpression of the profile (IL-6+, IL-1alpha+) in BPH patients with PSA between 0-4 and 4-20 ng/mL. However, PC patients with sera PSA between 4 and 20 ng/mL, showed a significant high immunoexpression of the profile (IL-6+, IL-1alpha-). This data demonstrate a locally production of pro-inflammatory cytokines by prostate epithelial cells and a cross talk between PSA and these cytokines in prostate pathologies.
Asunto(s)
Citocinas/análisis , Células Epiteliales/metabolismo , Antígeno Prostático Específico/sangre , Próstata/patología , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Células Epiteliales/patología , Humanos , Inflamación/metabolismo , Interleucina-1alfa/análisis , Interleucina-6/análisis , Masculino , Persona de Mediana Edad , ProteómicaRESUMEN
UNLABELLED: The aim of this study was to assess the role of thyroglobulin in monitoring patients with differentiated thyroid carcinoma. METHODS: We retrospectively sudied thirty patients who had total thyroidectomy and had been followed beteween 1999 and 2004 in nuclear medicine department. They have had iodine 131 whole body scans, repeated determination of thyroglobulin, thyreostimulin and thyroglobulin antibodies. RESULTS: One hundred twelve samples of thyroglobulin were done. In post surgical period thyroglobulin was ranging from 0.3 to 600 ng/ml. In 38 months follow up 4 patients (11.4%) had shown reccurent disease. Thyroglobulin sensitivity was 75%. One patient had diffuse lung metastases with high thyroglobulin level 600 ng/ml wich decreased after iodine 131 therapy. CONCLUSION: Serum thyroglobulin is the differentiated thyroid carcinoma marker of choice nevertheless one should establish the level of thyroid stimulation and seek for the antithyroglobulin antibodies.